Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version).
10.3779/j.issn.1009-3419.2021.101.13
- Author:
Caicun ZHOU
1
;
Jie WANG
2
;
Baocheng WANG
3
;
Ying CHENG
4
;
Zhehai WANG
5
;
Baohui HAN
6
;
You LU
7
;
Gang WU
8
;
Li ZHANG
9
;
Yong SONG
10
;
Bo ZHU
11
;
Yi HU
12
;
Ziping WANG
13
;
Qibin SONG
14
;
Shengxiang REN
1
;
Yayi HE
1
;
Xiaohua HU
15
;
Jian ZHANG
16
;
Yu YAO
17
;
Hongyun ZHAO
18
;
Zhijie WANG
2
;
Qian CHU
19
;
Jianchun DUAN
2
;
Jingjing LIU
4
;
Shukui QIN
20
Author Information
1. Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
2. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
3. No. 960 Hospital of PLA, Jinan 250031, China.
4. Jilin Cancer Hospital, Changchun 130012, China.
5. Shandong Cancer Hospital and Institute, Jinan 250117, China.
6. Shanghai Chest Hospital, Shanghai 200030, China.
7. West China Hospital, Sichuan University, Chengdu 610041, China.
8. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
9. Peking Union Medical College Hospital, Beijing 100010, China.
10. General Hospital of Eastern Theater Command, Nanjing 210002, China.
11. Xinqiao Hospital, The Army Medical University, Chongqing 400037, China.
12. Chinese PLA General Hospital, Beijing 100853, China.
13. Beijing Cancer Hospital, Beijing 100142, China.
14. Renmin Hospital of Wuhan University, Wuhan 430060, China.
15. The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
16. Xijing Hospital, Xi'an 710032, China.
17. The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
18. Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
19. Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
20. Cancer Center, Eastern Theater General Hospital of the Chinese PLA, Nanjing 210002, China.
- Publication Type:Journal Article
- Keywords:
Expert consensus;
Immunotherapy;
Lung neoplasms;
Programmed cell death protein 1/Programmed death-ligand 1
- From:
Chinese Journal of Lung Cancer
2021;24(4):217-235
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.
.
